Search

Displaying results 991 - 1000 of 10000 in total
  1. Drug

    Selenium

    go.drugbank.com/drugs/DB11135
    ApprovedInvestigationalVet approved

    Selenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen

    Mixtures: Multi II IV Vi Tab, Formula InfCategories: Compounds used in a research, industrial, or household setting
  2. Target

    Nuclear receptor subfamily 4 group A member 3

    go.drugbank.com/bio_entities/BE0008998
    TargetHumans

    Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. … Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription (By similarity).

    Synonyms: Translocated in extraskeletal chondrosarcoma
  3. Target

    Serine/threonine-protein kinase Nek4

    go.drugbank.com/bio_entities/BE0009498
    TargetHumans

    Required for normal cell cycle arrest in response to double-stranded DNA damage

    Synonyms: Never in mitosis A-related kinase 4
  4. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for

  5. Drug

    Arginine

    go.drugbank.com/drugs/DB00125
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is physiologically active in the L-form.

    Mixtures: Aminosyn II in Dextrose, Aminosyn II in Dextrose
  6. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development … [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]

  7. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.

  8. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.

    Synonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
  9. Drug

    Rosuvastatin

    go.drugbank.com/drugs/DB01098
    ApprovedInvestigational

    [A181087, A181406] Rosuvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [simvastatin], [fluvastatin], and [lovastatin] are considered first-line … found in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol.

    Categories: Drugs Used in DiabetesProducts: ROSUVASTATINA SPECIAL PRODUCT'S LINE
  10. Drug

    Octisalate

    go.drugbank.com/drugs/DB11062
    Approved

    It covers wavelength in the range 295-315 nm, peak at 307-310 nm. It is an ester of salicylic acid and 2-ethylhexanol. … Octyl salicylate is an oil soluble chemical sunscreen agent that absorbs UVB radiation. It does not protect against UVA. Octyl salicylate is used to augment the UVB protection in a sunscreen.

    Mixtures: The Ordinary Invisible Uv Filters SPF 35, The Ordinary Suncare Invisible UV Filters with Antioxidants SPF35Categories: Compounds used in a research, industrial, or household setting